Lonza expands microbial capacity and extends partnership with Servier for L-asparaginase API manufacturing
New mid-scale microbial facility will support Servier with API for acute lymphoblastic leukemia therapies.
Lonza's microbial manufacturing facility in Visp, Switzerland is poised for expansion so that it can provide mid-scale commercial manufacturing to multiple customers and serve the growing needs of Servier, an independent international pharmaceutical company and long-term Lonza partner.
Servier and Lonza have signed a long-term extension to the manufacturing agreement for L-asparaginase, produced at Lonza since 2009.
The extension and expansion of the collaboration will provide Servier with the additional capacity required to provide treatment to many more patients with acute lymphoblastic leukemia (ALL), a cancer of the white blood cells.
Servier intends to expand access to asparaginase-based multi-agent chemotherapeutic regimens, as ALL continues to be the most common type of cancer among children diagnosed with leukemia.
The new facility will be the sixth to be housed in Lonza’s new biopark in Visp, Switzerland, currently under construction.
The new mid-scale (3,000 L) microbial facility will tap into existing central utilities and labs and will complement the existing small-scale (1,000 L) and large-scale (15,000 L) assets in Visp. The facility is expected to be operational in the second half of 2022 and Lonza expects to add 100 new staff to the existing, highly-experienced microbial team.
Traditionally used for producing hormones, enzymes and some vaccines, microbial fermentation is becoming increasingly attractive for new molecular formats that do not need human glycosylation given the higher yields and shorter production timelines. For example, many antibody fragments, as well as plasmid DNA, can be produced in microbial systems.
Jean-Christoph Hyvert, Chief Commercial Officer, Lonza said: "We see a clear role for microbial technology as new medicines evolve and we are investing in key enablers including expression technology and manufacturing assets.”
Related News
-
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News The 2024 Pharma Outsourcing Forecast: strategic partnerships across global landscapes
For the pharmaceutical industry, outsourcing drug development, manufacturing, and research operations to contract organisations is not just a passing trend – increasingly, the partnership between drug sponsor and drug vendor is one of vital impor... -
News Gerresheimer predicts weight-loss drug deals to account for 4% of yearly growth
Dietmar Siemssen, CEO of German primary packaging manufacturer Gerresheimer, states that approximately 4% of the company’s revenue growth each year to come from deals with drugmakers of weight loss and diabetes products, particularly GLP-1 class ... -
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Coronary drug-coated medical device receives US FDA approval
Boston Scientific announced the FDA approval of their medical device AGENT Drug-Coated Balloon (DCB) for the indication of coronary in-stent restenosis in coronary artery disease patients. -
News CPHI Online Webinar Series – Innovative Strategies for B2B Pharma Marketeers
On February 20, 2024, CPHI Online hosted a webinar on Innovative Strategies for B2B Pharma Marketeers. Featuring expert speakers from across the pharmaceutical value chain, this webinar delves into how B2B pharma marketeers can create better content to... -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance